Go ahead. Thank you very much, and welcome to this Q1 2024 conference call, in which we will be reporting our progress of the last quarter. Next slide please. So this is a disclaimer slide that I will not ask you to read, obviously. Next slide please. Today I will go through the quarter overview and our results. I will also have some remarks about the PANTAX final data. And then Johnny will address the financial performance of the company. And then I will make some closing remarks summarizing where we stand and where we will be as a company. Next slide please. Before I go into the overview and review, I just would like to mention again that we are a very small team of senior-level executives, all of us with extensive experience in biopharma, pharma, and biotechnology. And then I would like to mention that we have a very strong clinical advisory board, especially Professor Bernie Rose. Some of you may have watched the interview he gave us during the R&D day we just had a few days ago in Stockholm that was broadcasted as well. So I would like to also mention that we have added two leading oncologists. Professor Pfeiffer from Copenhagen and Professor Michel Ducreux from Paris. Both are leading European clinical oncologists in the field of GI gastrointestinal diseases. And therefore, we are very well equipped to be advised on any future design of our clinical trials and also on how that will converge to what we call Scandion Oncology's next steps. Next slide please. So this is a slide that shows you the overview of our pipeline. And I would like to mention SCO-101, which is our lead compound that most of you know, is addressed in colorectal cancer and pancreatic cancer, not mentioned in gastric cancer as well. I would like to spend just one minute on SCO-201, SCO-201 is our follow-up compound and is currently on hold from a development perspective. Not because it is a bad compound, but because we need to make some prioritizations and that compound may be studied further in HIV/solid tumors. So to come back on SCO-101, so you see the clearest data, you see that we will be releasing the final data of the trial, part three, in H2 2024. With regard to contacts you have, some of you have noticed that we have released the final data a few days ago, actually. And I will come back to that as well. And, not to mention again, gastric cancer where we have good preclinical data and are what we call Phase 1B/2A ready. So this is the pipeline that fundamentally consists of our lead compound, SCO-101. Next slide please. These are the results of part three. And I would like you to pay a little bit of attention to that. Regarding the trial part three, we have observed in six patients two partial responses, meaning that the tumor shrinkage or the tumor reduction was more than 30%. And this is actually quite outstanding by all metrics in late-stage colorectal cancer patients. If you compare that number to a recent study, then you will find a 6% tumor reduction. Of course, our results need to be confirmed in a randomized clinical trial. But at least, no one can argue that we have had very good signs of clinical efficacy. At the same time, we had the CBR. So, the clinical benefit rate is 76% after eight weeks. And, if you compare it to another study that has been reported, the data is very good. Even more importantly, we have a promising median overall survival of close to eight months and a median progression-free survival of about 3.8 months. If you compare this progression-free survival (PFS). Free survival, with another study that has been recently released. Then, you get a number less than two months. So again, no one can argue that we haven't released significant data. We are really the company in drug resistance showing some significant data out of this phase IIa. And then finally, because we all know that the regulatory authorities will never accept any clinical development without a significant biomarker, we have been able to identify a biomarker for our next step and down the road, a randomized clinical trial called UGT1A1. And if we select patients with this biomarker, wildtype patients with colorectal cancer, then you get a median overall survival. Even better, a longer median overall survival of close to actually 14 months. And again, if you compare it to a recent study, yes, with many more patients, but still you only get a median of close to 11 months. So we have really good signs of clinical efficacy that I would like to also show you on the next slide. And this is a very important slide. And I couldn't resist showing it to you. You know, this is a 55-year-old female with RAS-mutated colon cancer, whom we have been treating since August 23rd, and she is still alive. And on the left-hand side, you could see, when we started the treatment, so you could see the tumor on the scan, quite a large one. And then, from August until December, you could see the very significant tumor shrinkage. That patient is still alive. That patient has a partial response. So this is what I wanted to show you as an example of our clinical efficacy. Now, furthermore, it's important to note that the other patients also had tumor shrinkage but with a lesser magnitude, between 6 and 25%, not reaching the 30% threshold. But still, we observed tumor reduction. Next slide, please. So if I could summarize very quickly, in parts one, two, and three; we could easily state we have a good safety and tolerability profile. Partial responses in two patients in the last cohort, of the six patients with a dosage of 250 mg on a four-day schedule, we have an impressive overall survival. Between 8 and 10 months. We have seen a significant increase in overall survival in a subgroup of patients expressing wildtype UGT1A1, from eight months to more than 30 months. And then, you know, what does that mean? That means that this data justifies the expansion of our series. Part three. And we need to enroll a small patient cohort in order to look at the maximum tolerated dose and examine the dosing regimen. So that will be further applied in a randomized clinical trial. Yes. Uh, the next slide will show you, uh, the data that has been recently released with regard to pancreatic cancer. Contacts with one being the maximum tolerated dose achieved is 200mg of alcoholic compounds. Uh, the PK data demonstrated that SCO-101 exposure is in line with our expectations. We had a partial response, and we had an overall response rate of 6.7% with a good CBR. Uh, progression-free survival was 2.5 months. Overall survival was 9.5 months. And, um, I have to say that, uh, these results are pretty good. And, uh, if we don't pursue the clinical development of pancreatic cancer, it's not because we lack the data; it's because we need to prioritize our relatively small level of resources onto colorectal cancer. And I think with that said, I will now pass the word to our dear CFO, Johnny. The floor is yours. Thank you. And if you look at this slide with the financial overview.